MannKind Corporation Participating at Upcoming Conferences
May 09 2022 - 6:00AM
MannKind Corporation (Nasdaq: MNKD), a company
focused on the development and commercialization of inhaled
therapeutic products for patients with endocrine and orphan lung
diseases, announced today that it will be participating at upcoming
conferences. Presenting from the Company will be its Chief
Executive Officer, Michael Castagna, PharmD.
- 2022 RBC Capital Markets Global Healthcare Conference –
Tuesday, May 17, 2022 at 11:00 am (ET)
- H.C. Wainwright Global Investment Conference – Tuesday, May 24,
2022 at 1:30 pm (ET)
Interested parties can access a link to the live webcast of the
presentations from the Events & Presentations section of the
Company’s website at
https://investors.mannkindcorp.com/events-and-presentations. The
webcast replay may be accessed at the same location for 14 days
following the live presentation.
About MannKind CorporationMannKind Corporation
(Nasdaq: MNKD) focuses on the development and commercialization of
inhaled therapeutic products for patients with endocrine and orphan
lung diseases. MannKind is currently commercializing Afrezza®
(insulin human) Inhalation Powder, the Company’s first FDA-approved
product and the only inhaled ultra rapid-acting mealtime insulin in
the United States, where it is available by prescription from
pharmacies nationwide. Afrezza is also available by prescription in
Brazil, where it is commercialized by the Company’s partner, Biomm
SA. MannKind was established in 1991, and is located in Danbury,
Conn., and Westlake Village, Calif. The Company also employs field
sales and medical representatives across the U.S. Please visit
mannkindcorp.com to learn more.
MANNKIND CONTACTS:Rose Alinaya, Investor
Relations(818) 661-5000Email: ir@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024